[144] Incyte Genomics Inc SEC Filing

Rhea-AI Filing Summary

Incyte Genomics' Form 144 records a proposed sale of 75,963 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,267,540.00. The shares were acquired via a stock option exercise on 08/13/2025 and payment was made in cash.

The filing also lists insider sales by Barry Flannelly totaling 27,472 shares in the past three months for gross proceeds of $2,040,893.53. The issuer reports 195,276,145 shares outstanding, so the proposed sale equals approximately 0.039% of outstanding shares. The document contains no earnings, guidance, or other operational details.

Insights

Financial Analyst

TL;DR Routine insider liquidity: planned sale is modest relative to outstanding shares and follows recent smaller disposals.

The proposed disposition of 75,963 shares for $6.27M appears to be an execution of compensation-related liquidity after a stock option exercise. Compared with the issuer's 195.28M shares outstanding, the planned sale represents about 0.039%, a negligible dilution or market-pressure signal on its own. Recent insider activity shows 27,472 shares sold for $2.04M over the past three months, indicating ongoing personal liquidity rather than a one-off large exit. No financial results or new material company information are included in the filing.

Corporate Governance Expert

TL;DR Disclosure is standard and complies with Rule 144 mechanics; no governance red flags in form content.

The filing documents a sale routed through an institutional broker and includes required acquisition details (stock option exercise) and payment method (cash), which supports procedural transparency. The identity shown in past sales, Barry Flannelly, and the broker (Morgan Stanley Smith Barney LLC) are explicitly listed. Because the amounts are small relative to total outstanding shares and the form contains no undisclosed operational issues, this notice is a routine insider reporting event rather than a governance concern.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	75963	6267540.00	195276145	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/13/2025	Stock Option Exercise	ISSUER			75963	08/13/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BARRY FLANNELLY 1801 Augustine Cut-Off Wilmington DE 19803	Common	08/12/2025	14037	1122969.83
BARRY FLANNELLY 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/16/2025	1340	91602.40
BARRY FLANNELLY 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/15/2025	1192	83273.12
BARRY FLANNELLY 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/03/2025	2809	191435.60
BARRY FLANNELLY 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/03/2025	8094	551612.58

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)